5 completed, 5 recruiting, 2 active not recruiting, 2 not yet recruiting. 16 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 5, Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Unknown 2 |
| Phase 2 | 9 | Completed 4, Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
Follow Long COVID: new trials by email Literature Review of Long COVID trials Research Report on Long COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition REGENECYTE, Placebo - Long COVID, Post-COVID-19 Condition | Phase 3 | Not yet recruiting | StemCyte, Inc. | 60 | 2026-03-31 | 2025-09-23 |
| Taurine Supplementation in Long COVID Taurine, Placebo - Long COVID | Phase 2 / Phase 3 | Recruiting | University of Alberta | 300 | 2025-11-18 | 2026-09-18 |
| Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study Pirfenidone, Placebo for pirfenidone, Upadacitinib - Long COVID | Phase 3 | Recruiting | Douglas D. Fraser | 348 | 2025-09-10 | 2026-10-06 |
| Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID Baricitinib, Placebo - Long COVID, Sars-CoV-2 Infection | Phase 3 | Recruiting | Wes Ely | 550 | 2024-10-21 | 2026-09-25 |
| Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial Hyperbaric oxygen - Post-COVID-19 Syndrome, Post-COVID Syndrome | Phase 3 | Unknown | Erasmus Medical Center | 120 | 2024-10-01 | 2024-02-28 |
| Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents Metformin, Placebo - Long COVID | Phase 3 | Unknown | Purpose Life Sciences | 16 | 2024-04-01 | 2024-03-04 |
| Study of LAU-7b for the Treatment of Long COVID in Adults LAU-7b for 3 cycles, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles - Long COVID | Phase 2 / Phase 3 | Completed | Laurent Pharmaceuticals Inc. | 272 | 2023-11-15 | 2026-01-06 |
| Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID) Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO) - Smell Dysfunction, Olfactory Disorder | Phase 2 / Phase 3 | Recruiting | Medical University of South Carolina | 145 | 2023-10-02 | 2026-04-02 |
| Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret] - Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 | Phase 2 / Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 182 | 2023-09-06 | 2026-01-08 |
| Pycnogenol® in Post-COVID-19 Condition Pycnogenol®, Placebo - Post COVID-19 Condition, Long COVID | Phase 3 | Completed | University of Zurich | 153 | 2023-06-07 | 2026-04-29 |
| RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Ibudilast, Pentoxifylline, Placebo - Long COVID, Post COVID Condition | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 460 | 2023-05-31 | 2026-02-23 |
| Fluvoxamine for Long COVID-19 Fluvoxamine - Long COVID | Phase 2 / Phase 3 | Completed | Washington University School of Medicine | 191 | 2023-05-15 | 2026-10-07 |
| Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19 Prednisolone, Losartan - COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle | Phase 3 | Active not recruiting | Valentina Puentmann | 279 | 2022-12-12 | 2025-12-09 |
| Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis Sirolimus - Pulmonary Fibrosis, COVID-19 Pneumonia | Phase 2 / Phase 3 | Active not recruiting | University of Chicago | 60 | 2021-07-09 | 2025-12-15 |
| Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers. sodium pyruvate nasal spray - Long COVID | Phase 2 / Phase 3 | Completed | Cellular Sciences, inc. | 22 | 2021-04-27 | 2022-03-09 |
Post-Acute COVID-19 Syndrome (16) · COVID-19 (7) · Anosmia (1) · Coronavirus Infections (1) · Fatigue Syndrome, Chronic (1) · Microvascular Angina (1) · Myocarditis (1) · Olfaction Disorders (1) · Pericarditis (1) · Pulmonary Fibrosis (1) · Vascular Remodeling (1) · Ventricular Dysfunction, Left (1) · Ventricular Remodeling (1)
Chronic Disease (16) · Coronaviridae Infections (16) · Disease Attributes (16) · Infections (16) · Lung Diseases (16) · Nidovirales Infections (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Pneumonia (16) · Pneumonia, Viral (16) · Post-Infectious Disorders (16) · RNA Virus Infections (16) · Respiratory Tract Diseases (16) · Respiratory Tract Infections (16) · Virus Diseases (16)
Atorvastatin (1) · Fenretinide (1) · Fluvoxamine (1) · Hyperbaric Oxygenation (1) · Interleukin 1 Receptor Antagonist Protein (1) · Losartan (1) · Maraviroc (1) · Metformin (1) · Olfactory Training (1) · Pentoxifylline (1) · Prednisolone (1) · Sirolimus (1) · Sugars (1) · Taurine (1) · Transcutaneous Electric Nerve Stimulation (1)
Cellular Sciences, inc. (1) · Douglas D. Fraser (1) · Erasmus Medical Center (1) · HealthBio, Inc. (1) · Hellenic Institute for the Study of Sepsis (1) · Laurent Pharmaceuticals Inc. (1) · Medical University of South Carolina (1) · Purpose Life Sciences (1) · StemCyte, Inc. (1) · University Health Network, Toronto (1) · University of Alberta (1) · University of Chicago (1) · University of Zurich (1) · Valentina Puentmann (1) · Washington University School of Medicine (1)
United States (7) · Canada (4) · Germany (2) · Italy (2) · Austria (1) · Brazil (1) · Greece (1) · Netherlands (1) · Pakistan (1) · South Africa (1) · Spain (1) · Switzerland (1) · Uganda (1) · Zambia (1)
Alexia Anagnostopoulos, MD (1) · Angela M Cheung, MD,PhD (1) · Ayodeji Adegunsoye, MD, MS (1) · Douglas D Fraser, MD, PhD, FRCPC (1) · Eike Nagel, MD, PhD (1) · Eric Lenze, MD (1) · Evangelos Giamarelos-Bourboulis, MD,PhD (1) · George Tomlinson, PhD (1) · Jahn S Fehr, Prof., MD (1) · Jean-Marie Houle, PhD (1) · Lawrence Richer, MD, MSc (1) · Peter Juni, MD, PhD (1) · Ronald Amen, PhD (1) · Valentina Puntmann, MD, PhD (1) · Wes Ely, M.D. (1)
PMID 38879571, PMID 42118816, PMID 42533000, PMID 42790915
2023 (1), R01AG085873 (1), R01DC021179 (1)